Please assess the completion status of the following clinical trial:

Trial Title: Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve for their stage IIIC/IV AJCC 8 non-small cell lung cancer with a tumor biopsy PD-L1 TPS \> 50%~* Intent to treat with PD-1/PD-L1 or PD-1/PD-L1 plus pemetrexed/carboplatin or paclitaxel/nab-paclitaxel/carboplatin~* ECOG PS 0-2~* Ability to consent to participate in the study~Exclusion Criteria:~* Ability to understand the requirements of the protocol or to provide informed consent is impaired or is unwilling to comply with the protocol requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PD1/PD-L1 (Type: None): Standard of Care: PD1/PD-L1 monotherapy
- PD1/PD-L1 + chemo (Type: None): Standard of Care: Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination

Based on this trial design, predict the completion outcome and termination type (if applicable).